Literature DB >> 32800556

High-mobility group box 1 induces bone destruction associated with advanced oral squamous cancer via RAGE and TLR4.

Yumi Sakamoto1, Tatsuo Okui2, Toshiyuki Yoneda3, Shoji Ryumon1, Tomoya Nakamura1, Hotaka Kawai4, Yuki Kunisada1, Soichiro Ibaragi1, Masanori Masui1, Kisho Ono1, Kyoichi Obata1, Tsuyoshi Shimo5, Akira Sasaki1.   

Abstract

Bone destruction of maxillary and mandibular bone by invasive oral squamous cell cancer (OSCC) raises various problems in the management of patients, resulting in poor outcomes and survival. However, the mechanism behind bone destruction by OSCC remains unclear. High-mobility group box 1 (HMGB1), a highly conserved ubiquitous nuclear non-histone DNA-binding protein, has been demonstrated to be secreted by aggressive cancers and regulate osteoclastogenesis, a central player during bone destruction. We therefore reasoned that HMGB1 secreted by OSCCs contributes to bone destruction. Our results showed that HMGB1 is produced by human cell lines of OSCC and promotes osteoclastogenesis via up-regulation of the expression of receptor activator of nuclear factor kappa-Β ligand in osteoblasts and osteocytes, and consequently osteoclastic bone destruction in mice. Further, we found that these actions of HMGB1 are mediated via the receptor for advanced glycation end products and toll-like receptors. These findings suggest that HMGB1 of OSCC and its down-stream signal pathways are potential targets for the treatment of bone destruction associated with advanced OSCC.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone destruction; HMGB1; Oral squamous cell cancer; Osteoclasts

Year:  2020        PMID: 32800556     DOI: 10.1016/j.bbrc.2020.07.120

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

Review 1.  Crosstalk Between Senescent Bone Cells and the Bone Tissue Microenvironment Influences Bone Fragility During Chronological Age and in Diabetes.

Authors:  Thibault Teissier; Vladislav Temkin; Rivka Dresner Pollak; Lynne S Cox
Journal:  Front Physiol       Date:  2022-03-21       Impact factor: 4.566

2.  The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.

Authors:  Liuyang Ren; Ying Lou; Mingyu Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.